Rydapt(midostaurin)

AML with FLT3 mutations; advanced systemic mastocytosis; SM with associated hematological neoplasm; mast cell leukemia.

1 DTP program

From $2,909/pack (56ct)

1 platform

FDA-Approved Indications

Newly diagnosed FLT3-mutation-positive AML (with chemo)Aggressive systemic mastocytosis, SM-AHN, or mast cell leukemia

Available direct-to-patient (DTP) programs

Sorted by price, lowest first. Always verify eligibility and pricing directly with the manufacturer.

Lowest price option

via Novartis Direct · Novartis

$2,909/pack (56ct)

78% off list price. Pack 56 (~14-day AML supply): $2,908.64. Pack 112 (~28-day SM supply): $5,817.28. Fulfilled through ASPN / Thrifty White.

Eligibility

Valid US prescription required. US residents only. HIPAA authorization required. Cell phone + text consent required for ASPN processing.

May purchase at cash price. Cannot seek reimbursement or count toward deductible.

Last verified: Mar 2026

Not sure which Rydapt program fits your situation?